Morningstar

Tiziana Life Sciences Ltd Ordinary Shares TLSA

Stock XNAS Rating as of Oct 16, 2026

News

Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

GlobeNewswire Oct 16, 2026, 11:00:00 AM
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)

GlobeNewswire Sep 30, 2026, 11:00:00 AM
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

GlobeNewswire Sep 21, 2026, 11:00:00 AM
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center

GlobeNewswire Sep 17, 2026, 11:00:00 AM
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

GlobeNewswire Aug 24, 2026, 11:00:00 AM
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

GlobeNewswire Aug 6, 2026, 11:00:00 AM
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

GlobeNewswire Aug 4, 2026, 11:00:00 AM
Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

GlobeNewswire Jul 31, 2026, 11:00:00 AM
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

GlobeNewswire Jul 22, 2026, 11:00:00 AM
Tiziana Life Sciences Plans to Spin Out Asset as Separate Company

Global News Select Dec 2, 2025, 12:52:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.